Skin and/or appendage neoplasm after Oclacitinib (Apoquel) in dogs
137 reports to the FDA describe skin and/or appendage neoplasm in dogs given Oclacitinib. That is 0.5% of all reports for this medicine, compared with 0.0% across reports for all dog medicines, so it is reported unusually often with this medicine.
137Reports
88%Marked serious
17%Recovered
8.8%Died or euthanised
107 daysTypical onset
Sponsored
How soon it started
How the animals did
Problems reported at the same time
Age of the animals
About this medicine
Oclacitinib controls itching from allergies (tablet, a JAK inhibitor).
Products with this ingredient include Apoquel. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.
Questions owners ask
- Can Oclacitinib cause skin and/or appendage neoplasm in dogs?
- 137 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
- How soon after a dose was it reported?
- In half of the reports with dates, it started within 107 days of the first dose.
- What should I do?
- Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).
Skin and/or appendage neoplasm with similar medicines
- Skin and/or appendage neoplasm after Cyclosporine (Atopica) 149 reports · 1.0% of its reports
All reported side effects of Oclacitinib in dogs · Medicines most reported with skin and/or appendage neoplasm